We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Council of Economic Advisers estimated that revenues for non-U.S. drugmakers would have been $194 billion higher in 2017 if foreign drug prices reflected the countries’ Gross Domestic Product. Read More